There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on POINT Biopharma Global (PNT – Research Report) and NewAmsterdam Pharma Company (NAMS – Research Report) with bullish sentiments.
POINT Biopharma Global (PNT)
In a report issued on May 15, Faisal Khurshid from SVB Securities reiterated a Buy rating on POINT Biopharma Global, with a price target of $14.00. The company’s shares closed last Tuesday at $10.77, close to its 52-week high of $11.13.
Khurshid has an average return of
According to TipRanks.com, Khurshid is ranked #1320 out of 8379 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for POINT Biopharma Global with a $14.80 average price target, implying a 42.0% upside from current levels. In a report released yesterday, Berenberg Bank also maintained a Buy rating on the stock with a $16.00 price target.
See the top stocks recommended by analysts >>
NewAmsterdam Pharma Company (NAMS)
In a report issued on May 15, Roanna Ruiz from SVB Securities reiterated a Buy rating on NewAmsterdam Pharma Company, with a price target of $21.00. The company’s shares closed last Tuesday at $12.95.
According to TipRanks.com, Ruiz is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NewAmsterdam Pharma Company with a $21.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PNT:
- POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
- POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
- PNT Upcoming Earnings Report: What to Expect?
- Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
- Lantheus, Point Biopharma announces FDA grants FTD for 177Lu-PNT2002
